论文部分内容阅读
目的探讨左卡尼汀联合复方α-酮酸片是否能改善腹膜相关性腹膜炎患者促红素抵抗的现象。方法选择2012年1月至2014年5月在深圳市福永人民医院肾内科规律腹膜透析治疗的60例作为研究对象。根据是否发生促红素抵抗现象,将其分为抵抗组和对照组,每组各30例。疗程3个月,记录并观察各组患者的用药依从性和各项实验室检查结果,根据上述指标进行分析。结果左卡尼汀联合复方α-酮酸片联合应用后,患者的用药依从性可,抵抗组的Hb、Hct、ALB、CRP、IL-6、SF、TSAT均明显优于对照组,差异有统计学意义(P<0.05);而两组的Ca2+、Cr、Bun差异无统计学意义(P>0.05)。结论综上所述,左卡尼汀联合复方α-酮酸片用于腹透相关性腹膜炎患者有助于提高机体的营养水平,改善微炎症状态,减少患者的促红素抵抗现象,从而改善肾性贫血症状,值得临床推广应用。
Objective To investigate whether levocarnitine combined with a-ketoacid tablets can improve the erythropoietin resistance in patients with peritoneal-associated peritonitis. Methods From January 2012 to May 2014, 60 patients undergoing peritoneal dialysis in the Department of Nephrology of Fuyong People’s Hospital of Shenzhen City were selected as research objects. According to whether the occurrence of erythropoietin resistance phenomenon, divided into resistance group and control group, each group of 30 cases. Treatment for 3 months, record and observe the medication compliance of each group of patients and the laboratory test results, according to the above indicators were analyzed. Results After the combination of levocarnitine and compound a-ketoacid tablets, the medication compliance of the patients was better than that of the control group, and the difference was significant (P <0.05). There was no significant difference in Ca2 +, Cr and Bun between the two groups (P> 0.05). Conclusion In summary, levocarnitine combined with a-ketoacid tablets in patients with peritoneal dialysis-related peritonitis help to improve the body’s nutritional status, improve the micro-inflammatory state, reduce the patient’s erythropoietin resistance, thus improving Renal anemia symptoms, worthy of clinical application.